Introduction
Over 400 million, including 34 million children, live with disabling hearing loss, affecting their health and quality of life. Hearing loss is a common hearing disorder disease with high occurrence and complex causes. Genetic factors are responsible for over 50% of hearing loss encountered in neonates, and account for nearly 40% of childhood hearing loss.
BGI have established a neonatal hearing screening strategy combined with genetic test for early detection of hereditary deafness by collecting microscopic blood samples from newborns and extracting DNA for high-throughput sequencing. The risk of hearing impairment in newborns will assessed by combining bioinformatics analysis.
OPTIONAL PANEL SUITABLE FOR
Option 1: Newborns pregnant couples with normal phenotype； Option 2: Deafness or hearing loss patient population with a family history of deafness or hearing loss
SAMPLE
DBS; Blood
TECHNOLOGY
Target Sequencing
Why Choose BGI NOVA™ Newborn Hereditary Hearing Loss Screening?
- Avoiding drug-induced Hearing Loss
- Avoiding late-onset hearing loss
- Predicting the outcome of CI
- Early detecton and Early intervention